CN101563100B - 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标 - Google Patents

用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标 Download PDF

Info

Publication number
CN101563100B
CN101563100B CN200780032092XA CN200780032092A CN101563100B CN 101563100 B CN101563100 B CN 101563100B CN 200780032092X A CN200780032092X A CN 200780032092XA CN 200780032092 A CN200780032092 A CN 200780032092A CN 101563100 B CN101563100 B CN 101563100B
Authority
CN
China
Prior art keywords
plasminogen
use according
periodontal
tissue
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780032092XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101563100A (zh
Inventor
托尔·尼
李季男
郭永志
托马斯·林德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhu Xu
Original Assignee
李季男
王天刚
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 李季男, 王天刚 filed Critical 李季男
Priority claimed from PCT/SE2007/050586 external-priority patent/WO2008027000A2/en
Publication of CN101563100A publication Critical patent/CN101563100A/zh
Application granted granted Critical
Publication of CN101563100B publication Critical patent/CN101563100B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
CN200780032092XA 2006-08-28 2007-08-28 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标 Active CN101563100B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82366506P 2006-08-28 2006-08-28
US60/823,665 2006-08-28
US94411107P 2007-06-15 2007-06-15
US60/944,111 2007-06-15
PCT/SE2007/050586 WO2008027000A2 (en) 2006-08-28 2007-08-28 Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health

Publications (2)

Publication Number Publication Date
CN101563100A CN101563100A (zh) 2009-10-21
CN101563100B true CN101563100B (zh) 2013-08-07

Family

ID=39136397

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780032092XA Active CN101563100B (zh) 2006-08-28 2007-08-28 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标
CN2007800324051A Active CN101573134B (zh) 2006-08-28 2007-08-28 抗感染候选药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007800324051A Active CN101573134B (zh) 2006-08-28 2007-08-28 抗感染候选药物

Country Status (12)

Country Link
US (3) US8318661B2 (https=)
EP (1) EP2056864B1 (https=)
JP (1) JP5566105B2 (https=)
KR (1) KR101517626B1 (https=)
CN (2) CN101563100B (https=)
AU (1) AU2007290881B2 (https=)
CA (1) CA2662101C (https=)
DK (1) DK2056864T3 (https=)
EA (1) EA016250B1 (https=)
ES (1) ES2451015T3 (https=)
MX (1) MX2009002226A (https=)
WO (1) WO2008026999A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
ES2453496T3 (es) 2006-08-28 2014-04-08 Omnio Healer Ab Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral
KR20120050442A (ko) 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
US20120189609A1 (en) 2009-08-28 2012-07-26 Thrombogenics Nv Improvement to trabeculectomy
RU2421192C1 (ru) * 2010-03-09 2011-06-20 Винера Гумаровна Нафикова Способ лечения хронического бактериального конъюнктивита
SG187201A1 (en) * 2010-07-26 2013-02-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
EP2661493B1 (en) 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
CN102507707B (zh) * 2011-10-12 2015-10-21 山东大学 一种检测龈沟液中蛋白裂解酶含量的方法
US10251946B2 (en) 2014-05-02 2019-04-09 Qu Biologics Inc. Anti-microbial immunomodulation
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
DK3391902T5 (da) 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
CA3008475C (en) * 2015-12-18 2024-06-04 Talengen International Limited Method for preventing and treating hepatic tissue injury and related disorders thereof
JP6793748B2 (ja) * 2015-12-18 2020-12-02 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 放射性および化学的損傷を予防及び治療するための方法
CN106890321A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防和治疗宫颈糜烂的方法
CN108463235A (zh) * 2015-12-18 2018-08-28 泰伦基国际有限公司 一种用于预防和治疗宫颈糜烂的方法
DK3395354T3 (da) 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
CN108463240A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
ES2982294T3 (es) 2015-12-18 2024-10-15 Talengen Int Ltd Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus
TWI746581B (zh) * 2016-12-15 2021-11-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途
JP7213552B2 (ja) * 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
CN108210900A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肥胖症的药物及其用途
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
CN110198732A (zh) * 2016-12-15 2019-09-03 泰伦基国际有限公司 一种促进胰岛素受体底物-2表达的方法
WO2018107686A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗动脉粥样硬化及其并发症的方法
JP7242057B2 (ja) * 2016-12-15 2023-03-20 タレンゲン インターナショナル リミテッド 薬物性腎損傷を予防及び治療するための方法
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN107496911A (zh) * 2017-10-20 2017-12-22 滕敏子 一种外科手术后用于防肿胀、抗感染的愈合剂
EP3883598A1 (en) * 2018-11-19 2021-09-29 Nordmark IP GmbH Ancrod for the treatment or prophylaxis of endocarditis
WO2021025043A1 (ja) * 2019-08-07 2021-02-11 学校法人東京歯科大学 判別方法、蛍光測定装置および検査薬
CN111742887A (zh) * 2019-12-19 2020-10-09 广西医科大学第一附属医院 放疗后分泌性中耳炎树鼩模型的建立方法
US20230081922A1 (en) * 2020-02-11 2023-03-16 Talengen International Limited Method and drug for treating viral pneumonia
WO2021180068A1 (zh) * 2020-03-09 2021-09-16 泰伦基国际有限公司 一种治疗2019新型冠状病毒引发疾病的方法和药物
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN115845036B (zh) * 2023-02-20 2023-05-09 滨州益洁口腔有限公司 用于口腔种植体牙龈组织的蛋白酶及制备方法
WO2025017211A1 (en) * 2023-07-20 2025-01-23 Katholieke Universiteit Leuven Treatment of staphylococcal abscesses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1420126A (zh) * 2002-07-10 2003-05-28 牛勃 一种重组人纤溶酶原Kringle5突变体蛋白rhPK－5的制备方法
WO2003045466A2 (en) * 2001-11-26 2003-06-05 Genentech, Inc. Catheter composition and uses thereof
CN1768138A (zh) * 2002-02-06 2006-05-03 N-酶生物技术有限公司 在微生物中生产重组蛋白质的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023143A (en) * 1959-10-14 1962-02-27 American Cyanamid Co Process for preparing a veterinary composition
AT402367B (de) 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5792835A (en) 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
US5397578A (en) * 1994-03-29 1995-03-14 Tovarischestvo S Ogranichennoi Otvetstvennostiju "Taurus" Method of treatment of chronic purulent inflammations of ear in children
US6372473B1 (en) 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US6420622B1 (en) * 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
JP2003513682A (ja) 1998-07-24 2003-04-15 ファーマカル、バイオテクノロジーズ、インコーポレーテッド 骨組織復元システムおよび方法
AU3862900A (en) 1999-03-01 2000-09-21 Uab Research Foundation Porous tissue scaffolding materials and uses thereof
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
ES2453496T3 (es) 2006-08-28 2014-04-08 Omnio Healer Ab Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045466A2 (en) * 2001-11-26 2003-06-05 Genentech, Inc. Catheter composition and uses thereof
CN1768138A (zh) * 2002-02-06 2006-05-03 N-酶生物技术有限公司 在微生物中生产重组蛋白质的方法
CN1420126A (zh) * 2002-07-10 2003-05-28 牛勃 一种重组人纤溶酶原Kringle5突变体蛋白rhPK－5的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Crispian Scully等.Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia).《ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY》.2001,第91卷(第3期),334-337. *
Rams TE等.Staphylococci in human.<Oral Microbiol Immtmol>.1990,第5卷29-32. *
Tao Jin等.Urokinase-Type Plasminogen Activator,an Endogenous Antibiotic.《JID》.2005,第192卷429-437. *

Also Published As

Publication number Publication date
CN101573134B (zh) 2013-03-06
CN101573134A (zh) 2009-11-04
US20130149321A1 (en) 2013-06-13
EP2056864B1 (en) 2013-12-11
JP2010502600A (ja) 2010-01-28
WO2008026999A2 (en) 2008-03-06
US8318661B2 (en) 2012-11-27
AU2007290881A1 (en) 2008-03-06
DK2056864T3 (en) 2014-03-10
EA016250B1 (ru) 2012-03-30
US20100099600A1 (en) 2010-04-22
KR20090059122A (ko) 2009-06-10
KR101517626B1 (ko) 2015-05-07
EA200970233A1 (ru) 2009-08-28
EP2056864A2 (en) 2009-05-13
CA2662101C (en) 2015-07-07
WO2008026999A3 (en) 2008-05-22
MX2009002226A (es) 2009-09-07
US10729750B2 (en) 2020-08-04
ES2451015T3 (es) 2014-03-26
AU2007290881B2 (en) 2013-03-07
CA2662101A1 (en) 2008-03-06
US20160243204A1 (en) 2016-08-25
CN101563100A (zh) 2009-10-21
EP2056864A4 (en) 2012-01-25
JP5566105B2 (ja) 2014-08-06

Similar Documents

Publication Publication Date Title
CN101563100B (zh) 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标
US10086052B2 (en) Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
RU2241489C2 (ru) Композиции матриксных протеинов для залечивания ран
JP5024866B2 (ja) 創傷治癒のためのマトリックスタンパク質組成物
Falanga The chronic wound: impaired healing and solutions in the context of wound bed preparation
Brand et al. Saliva and wound healing
Papanas et al. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?
JP2007291115A6 (ja) 創傷治癒のためのマトリックスタンパク質組成物
JP2017509599A (ja) 皮膚潰瘍及び創傷の治癒を促進するための組成物
ES2883147T3 (es) Composiciones y métodos para el tratamiento de heridas crónicas
ES2467668T3 (es) Composicón farmaceutica, vendaje y método para tratar lesión cutánea, composición intermedia y proceso para preparar dicho vendaje y uso de sal de cerio asociada con una matriz de colágeno
Cui et al. Clinical efficacy of chlorhexidine gargle combined with recombinant bovine basic fibroblast growth factor gel in the treatment of recurrent oral ulcers and its effects on inflammatory factors, immune function, and recurrence rate
JP2017513944A (ja) 異常な皮膚瘢痕化の治療
HK1134788B (en) Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
Irmawati et al. Healing Process on the Oral Traumatic Ulcer (OTU): A Review
Kondo et al. Increased expression of angiopoietin‐like protein 4 regulates matrix metalloproteinase‐13 expression in Porphyromonas gingivalis lipopolysaccharides‐stimulated gingival fibroblasts and ligature‐induced experimental periodontitis
Kamal et al. Research Article The Efficacy of Concentrated Growth Factor in the Healing of Alveolar Osteitis: A Clinical Study
Delima Pre-Wounding and Free Gingival Grafts: A Pilot Investigation
Schultz et al. Wound Débridement
CZ20002986A3 (cs) Prostředky na bázi proteinů matrice pro hojení ran
HK1136204A (en) Candidates against infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1134788

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: WYF INNOVATION UMEA AB

Free format text: FORMER OWNER: OMNIO HEALER AB

Effective date: 20121128

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20121128

Address after: Swedish chicken

Applicant after: WYF innovation excellence Co.

Address before: Swedish chicken

Applicant before: Omni Treatment Co.,Ltd.

ASS Succession or assignment of patent right

Owner name: WANG TIANGANG

Effective date: 20121204

Owner name: LI JINAN

Free format text: FORMER OWNER: WYF INNOVATION UMEA AB

Effective date: 20121204

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; TO: 100000 CHAOYANG, BEIJING

TA01 Transfer of patent application right

Effective date of registration: 20121204

Address after: 100000, Beijing, Chaoyang District Zhuang Jia Zhuang No. 8 (booming Park South Gate) Rui Jian International Nursing

Applicant after: Li Jinan

Applicant after: Wang Tiangang

Address before: Swedish chicken

Applicant before: WYF innovation excellence Co.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1134788

Country of ref document: HK

ASS Succession or assignment of patent right

Free format text: FORMER OWNER: WANG TIANGANG

Effective date: 20140717

Owner name: SHENZHEN TIANRUI RENJIAN BIOTECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: LI JINAN

Effective date: 20140717

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 100000 CHAOYANG, BEIJING TO: 518057 SHENZHEN, GUANGDONG PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20140717

Address after: 518057, No. 13, Building 29, overseas student building, No. 11, South Ring Road, Nanshan District hi tech Zone, Shenzhen

Patentee after: Shenzhen days of Kin Kin Kin Biological Technology Co.,Ltd.

Address before: 100000, Beijing, Chaoyang District Zhuang Jia Zhuang No. 8 (booming Park South Gate) Rui Jian International Nursing

Patentee before: Li Jinan

Patentee before: Wang Tiangang

ASS Succession or assignment of patent right

Owner name: SHENZHEN RUIJIAN LIFE SCIENCES INSTITUTE CO., LTD.

Free format text: FORMER OWNER: SHENZHEN TIANRUI RENJIAN BIOTECHNOLOGY CO., LTD.

Effective date: 20150327

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 518057 SHENZHEN, GUANGDONG PROVINCE TO: 518000 SHENZHEN, GUANGDONG PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20150327

Address after: 518000, Guangdong, Shenzhen, Futian District Futian street, Shennan Road, No. 1006, Shenzhen International Innovation Center, C building, 19 floor, 19-002

Patentee after: TALENGEN INSTITUTE OF LIFE SCIENCES, Co.,Ltd.

Address before: 518057, No. 13, building 11, overseas student building, 29 South Ring Road, Nanshan District hi tech Zone, Guangdong, Shenzhen

Patentee before: Shenzhen days of Kin Kin Kin Biological Technology Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200106

Address after: Unit 702, unit 1, building 1, Zhongtai community, No. 2088, Honggui Road, Guiyuan street, Luohu District, Shenzhen City, Guangdong Province

Patentee after: Shenzhen days of Kin Kin Kin Biological Technology Co.,Ltd.

Address before: 518000 19-002, floor 19, building C, Shenzhen International Innovation Center, No. 1006, Shennan Avenue, Futian street, Futian District, Shenzhen

Patentee before: TALENGEN INSTITUTE OF LIFE SCIENCES, Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220624

Address after: 075061 No. 101, unit 2, building 12, xiadongying, Qiaoxi District, Zhangjiakou City, Hebei Province

Patentee after: Zhu Xu

Address before: 518057 room 702, unit 1, building 1, Zhongtai community, 2088 Honggui Road, Guiyuan street, Luohu District, Shenzhen City, Guangdong Province

Patentee before: Shenzhen days of Kin Kin Kin Biological Technology Co.,Ltd.